Many people with post-traumatic stress disorder (PTSD) spend years navigating trial-and-error treatment strategies that do not adequately manage their symptoms. Anecdotal reports suggest ibogaine may rapidly affect PTSD symptoms in some people, but as of September 2026, no clinical research studies existed in the United States to investigate ibogaine-based PTSD treatment. This project proposes a design and Investigational New Drug clinical research phase that lays the regulatory, chemical, and engineering foundation for a domestically manufactured, single-molecule ibogaine hydrochloride drug product for potential PTSD treatment that can be regulated by the U.S. Food and Drug Administration.